Branched Chain Amino Acids for Sarcopenia in Patients Undergoing Total Knee Arthroplasty

This multicenter, prospective, randomized controlled trial evaluates whether postoperative administration of branched chain amino acids affects skeletal muscle mass index and sarcopenia related functional outcomes in patients undergoing total knee arthroplasty. Participants are randomly assigned to receive Livact granules 4.15 g three times daily for 3 months after surgery or to receive standard postoperative care without branched chain amino acid administration. Skeletal muscle mass index, physical function, patient reported outcomes, laboratory findings, medication compliance, and adverse events are assessed at baseline, 5 weeks, and 15 weeks after surgery.

NCT Number	NCT07634523
Lead Sponsor	Seoul National University Hospital Collaborators: Samil Pharmaceutical Co., Ltd.
Conditions	Sarcopenia, Total Knee Arthroplasty
Enrollment	140 participants
Start Date	2025-02-06
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-09